Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Ann Oncol ; 31(5): 590-598, 2020 05.
Article in English | MEDLINE | ID: mdl-32245699

ABSTRACT

BACKGROUND: Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance in clinical cohorts may point to strategies to prevent or overcome treatment failure. PATIENTS AND METHODS: We obtained tumor biopsies from metastatic breast cancer patients with BRCA1/2 deficiency before and after acquired resistance to PARPi or platinum chemotherapy. Whole exome sequencing was carried out on each tumor, germline DNA, and circulating tumor DNA. Tumors underwent RNA sequencing, and immunohistochemical staining for RAD51 foci on tumor sections was carried out for functional assessment of intact homologous recombination (HR). RESULTS: Pre- and post-resistance tumor samples were sequenced from eight patients (four with BRCA1 and four with BRCA2 mutation; four treated with PARPi and four with platinum). Following disease progression on DNA-damaging therapy, four patients (50%) acquired at least one somatic reversion alteration likely to result in functional BRCA1/2 protein detected by tumor or circulating tumor DNA sequencing. Two patients with germline BRCA1 deficiency acquired genomic alterations anticipated to restore HR through increased DNA end resection: loss of TP53BP1 in one patient and amplification of MRE11A in another. RAD51 foci were acquired post-resistance in all patients with genomic reversion, consistent with reconstitution of HR. All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy. CONCLUSIONS: Genomic reversion in BRCA1/2 was the most commonly observed mechanism of resistance, occurring in four of eight patients. Novel sequence alterations leading to increased DNA end resection were seen in two patients, and may be targetable for therapeutic benefit. The presence of RAD51 foci by immunohistochemistry was consistent with BRCA1/2 protein functional status from genomic data and predicted response to later DNA-damaging therapy, supporting RAD51 focus formation as a clinically useful biomarker.


Subject(s)
Breast Neoplasms , Ovarian Neoplasms , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Drug Resistance, Neoplasm/genetics , Female , Humans , Ovarian Neoplasms/drug therapy , Platinum/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
2.
Curr Biol ; 8(21): 1191-4, 1998 Oct 22.
Article in English | MEDLINE | ID: mdl-9799736

ABSTRACT

What visual information do we use to guide movement through our environment? Self-movement produces a pattern of motion on the retina, called optic flow. During translation, the direction of movement (locomotor direction) is specified by the point in the flow field from which the motion vectors radiate - the focus of expansion (FoE) [1-3]. If an eye movement is made, however, the FoE no longer specifies locomotor direction [4], but the 'heading' direction can still be judged accurately [5]. Models have been proposed that remove confounding rotational motion due to eye movements by decomposing the retinal flow into its separable translational and rotational components ([6-7] are early examples). An alternative theory is based upon the use of invariants in the retinal flow field [8]. The assumption underpinning all these models (see also [9-11]), and associated psychophysical [5,12,13] and neurophysiological studies [14-16], is that locomotive heading is guided by optic flow. In this paper we challenge that assumption for the control of direction of locomotion on foot. Here we have explored the role of perceived location by recording the walking trajectories of people wearing displacing prism glasses. The results suggest that perceived location, rather than optic or retinal flow, is the predominant cue that guides locomotion on foot.


Subject(s)
Locomotion/physiology , Perceptual Disorders/physiopathology , Psychomotor Performance/physiology , Vision Disorders/physiopathology , Adult , Functional Laterality , Humans , Male , Retina/physiopathology , Visual Perception/physiology
3.
J Cell Physiol ; 176(2): 266-80, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9648914

ABSTRACT

Murine embryonic palate mesenchyme (MEPM) cells are responsive to a number of endogenous factors found in the local embryonic tissue environment. Recently, it was shown that activation of the cyclic AMP (cAMP) or the transforming growth factor beta (TGFbeta) signal transduction pathways modulates the proliferative response of MEPM cells to epidermal growth factor (EGF). Since the mitogen-activated protein kinase (MAPK) cascade is a signal transduction pathway that mediates cellular responsiveness to EGF, we examined the possibility that several signaling pathways which abrogate EGF-stimulated proliferation do so via the p42/p44 MAPK signaling pathway. We demonstrate that EGF stimulates MAPK phosphorylation and activity in MEPM cells maximally at 5 minutes. Tyrosine phosphorylation and activation of MAPK was unaffected by treatment of MEPM cells with TGFbeta or cholera toxin. Similarly, TGFbeta altered neither EGF-induced MAPK tyrosine phosphorylation nor activity. However, the calcium ionophore, A23187, significantly increased MAPK phosphorylation which was further increased in the presence of EGF, although calcium mobilization reduced EGF-induced proliferation. Despite the increase in phosphorylation, we could not demonstrate induction of MAPK activity by A23187. Like EGF, phorbol ester, under conditions which activate PKC isozymes in MEPM cells, increased MAPK phosphorylation and activity but was also growth inhibitory to MEPM cells. The MEK inhibitor, PD098059, only partially abrogated EGF-induced phosphorylation. Likewise, depletion of PKC isozymes partially abrogated EGF-induced MAPK phosphorylation. Inhibition of both MEK and PKC isozymes resulted in a marked decrease in MAPK activity, confirming that EGF uses multiple pathways to stimulate MAPK activity. These data indicate that the MAPK cascade does not mediate signal transduction of several agents that inhibit growth in MEPM cells, and that there is a dissociation of the proliferative response and MAP kinase activation. Furthermore, other signaling pathways known to play significant roles in differentiation of palatal tissue converge with the MAPK cascade and may use this pathway in the regulation of alternative cellular processes.


Subject(s)
Fetus/cytology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase Kinases , Palate/cytology , Palate/enzymology , Sulfonamides , Animals , Calcimycin/pharmacology , Carcinogens/pharmacology , Cells, Cultured , Cholera Toxin/pharmacology , Cyclic AMP/metabolism , Endothelial Growth Factors/pharmacology , Endothelial Growth Factors/physiology , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Fetus/drug effects , Fetus/enzymology , Flavonoids/pharmacology , Ionophores/pharmacology , Isoquinolines/pharmacology , MAP Kinase Kinase 1 , MAP Kinase Kinase 2 , Mice , Mice, Inbred ICR , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/biosynthesis , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/biosynthesis , Protein-Tyrosine Kinases/metabolism , Signal Transduction/drug effects , Tetradecanoylphorbol Acetate/pharmacology , Transforming Growth Factor beta/pharmacology
4.
Exp Cell Res ; 231(1): 96-103, 1997 Feb 25.
Article in English | MEDLINE | ID: mdl-9056415

ABSTRACT

A number of studies over the last several years have demonstrated a crucial role for TGF-beta in epithelial and mesenchymal differentiation during development of the embryonic palate. Molecular mechanism(s) of signal transduction responsible for eliciting these responses remain unresolved. Since cAMP signaling also modulates the same tissue differentiation in the developing palate and palate-derived cells, we hypothesized that TGF-beta activity may be mediated through cAMP-inducible pathways. We thus examined the effects of TGF-beta on activation of the cAMP regulatory element binding protein CREB, a nuclear transcription factor which mediates transcription of genes containing CRE recognition sequences in their promoters. We examined the ability of TGF-beta-treated murine embryonic palate mesenchymal (MEPM) cells to phosphorylate CREB on the amino acid residue serine 133, phosphorylation of which is indispensable for transcriptional activation. TGF-beta treatment led to increased phosphorylation of CREB ser-133 in a time- and dose-dependent manner. Inhibition of serine-threonine phosphatases by okadaic acid enhanced but did not prolong this response. TGF-beta failed to induce the activity of protein kinase A (PKA), a known CREB kinase. Inhibition of either PKA or calcium/calmodulin kinase II (CaMK II) did not abrogate phosphorylation of CREB by TGF-beta. TGF-beta treatment also did not induce phosphorylation of mitogen-activated protein kinases, erk-1 and erk-2, on tyrosine 185, suggesting that these kinases do not mediate CREB phosphorylation by TGF-beta. Additionally, TGF-beta had no effect on CREB binding to known CREB DNA consensus recognition sequences, CRE and TRE. Together, these data suggest an alternative or novel CREB kinase in MEPM cells through which TGF-beta acts to induce CREB ser-133 phosphorylation and subsequent activation of CRE-containing genes.


Subject(s)
Cyclic AMP Response Element-Binding Protein/metabolism , Palate/embryology , Signal Transduction , Transforming Growth Factor beta/pharmacology , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2 , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cells, Cultured , Cholera Toxin/pharmacology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/metabolism , DNA/metabolism , Enzyme Inhibitors/pharmacology , Mesoderm/cytology , Mesoderm/metabolism , Mice , Mice, Inbred ICR , Okadaic Acid/pharmacology , Palate/cytology , Palate/metabolism , Phosphorylation , Phosphoserine , Protein Serine-Threonine Kinases/metabolism , Regulatory Sequences, Nucleic Acid , Ribosomal Protein S6 Kinases
5.
J Cell Physiol ; 163(3): 431-40, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7775586

ABSTRACT

Normal growth and differentiation of embryonic palatal tissue depends on regulated levels of intracellular cAMP. Cyclic AMP-dependent protein kinases (PKA) act to mediate the biological activities of cAMP. PKA isozyme protein profiles demonstrate a clear pattern of temporal alterations in embryonic palatal tissue during its development. In order to ascertain the molecular basis for changing PKA isozyme profiles during palatal ontogeny, the spatial and temporal expression of mRNAs for regulatory (RI alpha, RII alpha, and RII beta) and catalytic (C alpha) subunits of PKA was examined. RNA extracted from murine embryonic palatal tissue (days 12-14 of gestation) was examined by Northern blot analysis. Significant levels of constitutively expressed RI alpha and C alpha mRNA were seen on all days of gestation examined. RI alpha transcripts were substantially less abundant in palate mesenchymal cells in vitro than in palatal tissue in vivo. Levels of RII alpha and RII beta mRNA were highest on gestational day (GD) 12, a period characterized by pronounced palatal tissue growth. In addition, patterns of tissue distribution of RII beta, not previously described, were examined in the developing embryonic palate. A dramatic developmental shift in tissue distribution of RII beta was seen. The isozyme was evenly distributed between palatal epithelial and mesenchymal cells on GD 12 but by GD 14, RII beta was predominantly localized to palatal epithelial cells. Direct activation of adenylate cyclase with forskolin in murine embryonic palate mesenchymal (MEPM) cells resulted in an increase in RII alpha mRNA levels but had no effect on steady state levels of RII beta or C alpha mRNA. In addition, elevation of intracellular levels of cAMP resulted in a shift in the transcriptional profile of RI alpha mRNAs. Results of this study document specific patterns of expression for the genes encoding the various cAMP-dependent protein kinase regulatory and C alpha subunits in murine embryonic palatal tissue. In addition, we have demonstrated adaptational changes of this kinase in MEPM cells in response to conditions of increased intracellular levels of cAMP.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/genetics , Fetus/physiology , Gene Expression , Palate/embryology , Animals , Cells, Cultured , Cyclic AMP/metabolism , Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit , Cyclic AMP-Dependent Protein Kinase RIalpha Subunit , Cyclic AMP-Dependent Protein Kinase RIbeta Subunit , Female , Immunohistochemistry , Intracellular Membranes/metabolism , Male , Mice , Mice, Inbred ICR , RNA, Messenger/metabolism
6.
In Vitro Cell Dev Biol ; 28A(11-12): 755-62, 1992.
Article in English | MEDLINE | ID: mdl-1282915

ABSTRACT

Growth and differentiation of cells derived from the embryonic palate are critically dependent on the intracellular cAMP-mediated signal transduction pathway. Human embryonic palate mesenchymal (HEPM) cells have been widely used to examine the effect of teratogens on palatal tissue growth and differentiation, as well as a prescreen for environmental teratogens. This study examined responsiveness of HEPM cells to agents known to stimulate adenylate cyclase, characterized cAMP-dependent protein kinases (cAMP-dPK) (EC 2.7.1.37) and investigated to what extent HEPM cells reveal adaptational responses to cAMP at the level of cAMP-dependent protein kinase. HEPM cells exhibited a total cell cycle transit time of approximately 22 h and responded maximally, when confluent, to prostacyclin (PGI2), prostaglandin E2 (PGE2), and isoproterenol with time- and dose-dependent increases in intracellular levels of cAMP. The order of sensitivity to hormonal activation of adenylate cyclase was PGE2 > isoproterenol > PGI2. Basal cAMP-dependent protein kinases activity was 0.184 fmol phosphate transferred from ATP to histone per microgram protein per minute under conditions where endogenous phosphatases did not significantly affect protein phosphorylation. Regulatory subunits of cAMP-dPK in HEPM cells were characterized by the binding of [3H]cAMP to cytosolic fractions. Specific binding was saturable at approximately 50 nM indicating the presence of binding sites that are finite in number. Calculation of half-maximal binding yielded an estimated Kd of 25 nM indicating the presence of high affinity binding sites. Cyclic AMP-dPK regulatory subunits were also photoaffinity labeled with 8-N3-[32P]-cAMP, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and radiolabeled bands visualized by autoradiography. Photoactivated incorporation of 8-N3-[32P]cAMP was detected into two proteins of molecular weight (M(r)) 45,000 and M(r) 51,000 representing, respectively, the RI alpha and RII beta subunits of cAMP-dPK. Binding of [32P]8-azido cAMP to proteins of M(r) 45,000 (RI alpha) and M(r) 51,000 (RII beta) was increased in response to elevation of intracellular cAMP via inhibition of its breakdown with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, or by direct activation of adenylate cyclase with forskolin. HEPM cells thus revealed adaptational responses to cAMP at the level of cAMP-dependent protein kinase. Characterization of the cAMP signal transduction pathway in HEPM cells, derived from embryonic palatal tissue which is critically dependent on this pathway for normal development, may provide information fundamental to a clear understanding of cellular events involved in palatal ontogeny. These results highlight several important differences between HEPM cells and murine embryonic palate mesenchymal cells.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Mesoderm/cytology , Mesoderm/enzymology , Palate/cytology , Palate/embryology , Protein Kinases/analysis , 1-Methyl-3-isobutylxanthine/pharmacology , Adenylyl Cyclases/metabolism , Cell Differentiation , Cell Division/drug effects , Cells, Cultured , Colforsin/pharmacology , Cyclic AMP/pharmacology , Dinoprostone/pharmacology , Dose-Response Relationship, Drug , Electrophoresis, Polyacrylamide Gel , Enzyme Activation/drug effects , Epoprostenol/pharmacology , Fetus/cytology , Fetus/enzymology , Humans , Isoproterenol/pharmacology , Signal Transduction/physiology , Time Factors
7.
J Craniofac Genet Dev Biol ; 11(4): 262-76, 1991.
Article in English | MEDLINE | ID: mdl-1667402

ABSTRACT

Investigations of the pathogenesis of cleft palate have been hampered by the complexity of normal craniofacial ontogenesis and by an incomplete understanding of mechanisms involved in normal palate development. This article deals with cellular aspects of the developing craniofacial region and discusses the facts and problems in the field as they relate to the normal development of the secondary palate, with emphasis on the regulation of hormone- and growth factor-induced transmembrane signalling and intracellular signal transduction.


Subject(s)
Cell Communication/physiology , Palate/embryology , Signal Transduction/physiology , Animals , Catecholamines/physiology , Cell Differentiation/physiology , Cell Division/physiology , Cricetinae , Cyclic AMP/biosynthesis , DNA/biosynthesis , Epidermal Growth Factor/physiology , Gene Expression Regulation , Humans , Mice , Prostaglandins/physiology , Protein Kinases/physiology , Rats , Second Messenger Systems/physiology , Transforming Growth Factor beta/physiology
8.
J Craniofac Genet Dev Biol ; 9(2): 161-72, 1989.
Article in English | MEDLINE | ID: mdl-2551918

ABSTRACT

Temporally and quantitatively coordinated synthesis of cyclic adenosine monophosphate appears to be critical for normal development of the mammalian secondary palate. Calmodulin has been implicated as being involved in mediating the activity of a number of fundamental calcium-regulated intracellular enzyme systems including phosphodiesterases, adenylate cyclase, and a variety of kinases, all of which may regulate or be regulated by intracellular cAMP. Calmodulin levels were thus quantified, and endogenous calmodulin was immunolocalized in developing palatal tissue in vivo and in embryonic palatal mesenchymal cells in vitro. Endogenous palatal calmodulin levels, determined by radioimmunoassay, showed little variation during the period of murine palatal ontogenesis and averaged 0.23 ng/micrograms protein. Murine palate mesenchymal cells in monolayer, either in logarithmic growth or at confluency, contained similar levels of calmodulin. In palate mesenchymal cells in primary culture, specific anti-calmodulin staining was confined to the cell cytoplasm and was concentrated in the perinuclear region. Since immunostaining for calmodulin appeared to be associated with discrete cytoplasmic filaments, distribution of actin and tubulin were investigated. Immunostaining for tubulin in these cells was also localized to the perinuclear region, while immunolocalization of actin showed staining patterns, reflective of stress fibers, which were quite different from those seen for calmodulin. Immunostaining was seen in vivo in all regions of the palatal epithelium with superficial peridermal cells staining most intensely. Specific immunostaining was also evident in palatal mesenchyme, where a pericellular distribution was seen. Staining patterns were similar throughout the period of palatal ontogeny. In addition, a sharply defined localization of calmodulin to cartilagenous extracellular matrix was noted. This study provides a useful initial approach toward understanding the role calmodulin may play in embryonic orofacial development.


Subject(s)
Calmodulin/analysis , Palate/embryology , Animals , Cells, Cultured , Cyclic AMP/physiology , Female , Immunohistochemistry , Male , Mice , Mice, Inbred C57BL , Palate/analysis , Radioimmunoassay
9.
J Craniofac Genet Dev Biol ; 9(2): 207-22, 1989.
Article in English | MEDLINE | ID: mdl-2794008

ABSTRACT

Certain hormonal primary messengers identified in the mammalian palate during its ontogeny transmit information to the interior of the cell via transmembrane signaling systems that control the production of the secondary messenger cyclic adenosine monophosphate. The singular role of intracellular cyclic AMP is to activate cAMP-dependent protein kinases (cAMP-dPK). cAMP-dPK were thus identified and characterized in the developing murine embryonic palate. Incubation of cytosolic fractions of embryonic palatal tissue with cAMP resulted in a dose-dependent increase in the cAMP-dPK activity ratio. A transient elevation of basal cAMP-dPK was seen during the period of palatal ontogeny that corresponded temporally with a previously demonstrated transient elevation of palatal basal cAMP levels. Fractions of embryonic palatal tissue cytosols derived by diethylaminoethyl (DEAE)-Sephacel chromatography were analyzed for phosphotransferase activity and for [3H]-cAMP binding to the regulatory (R) subunits of cAMP-dPK. Such analyses revealed two peaks of activity on day 13 of gestation. Based on the salt concentration at which the material in these peaks eluted from DEAE, its ability to cochromatograph with authentic cAMP-dPK isozymes, its molecular weight as determined by sodium dodecyl sulfate-polycrylamide gel electrophoresis, and the ability of the material to be photoaffinity labeled with [3H]-8-azidoadenosine 3',5' cyclic phosphate, types I and II cAMP-dPK were identified. Regulatory subunits of cAMP-dPK were characterized by the binding of [3H]-cAMP to cytosolic fractions of embryonic palatal tissue. Such binding was saturable (Bmax = 1,096 fmol/mg protein) and of high affinity (Kd = 7 nM). Only cAMP and cyclic guanosine monophosphate competed in a dose-related manner with [3H]-cAMP for binding to R subunits of cAMP-dPK. Adenosine, cTMP, and adenosine triphosphate, at doses up to 10(-4) M, did not compete for binding. Temporal analysis of binding data indicated that the number of binding sites transiently decreased during day 13 of gestation. Characterization of cAMP-dPK in tissue derived from the developing mammalian palate allows consideration of cAMP-dPK as a key regulatory enzyme capable of transducing hormonally elevated intracellular levels of cAMP into metabolic responses during orofacial ontogenesis.


Subject(s)
Isoenzymes/metabolism , Maxilla/embryology , Palate/embryology , Protein Kinases/metabolism , Animals , Autoradiography , Chromatography, DEAE-Cellulose , Histones , Maxilla/enzymology , Mice , Mice, Inbred C57BL , Palate/enzymology , Phosphorylation , Protein Kinases/pharmacokinetics
11.
Biochem Biophys Res Commun ; 130(3): 1037-43, 1985 Aug 15.
Article in English | MEDLINE | ID: mdl-2992494

ABSTRACT

The influence of epidermal growth factor (EGF) on the ability of murine embryonic palate mesenchymal (MEPM) cells to be stimulated to synthesize cAMP and prostaglandins was investigated. Preincubation of MEPM cells with EGF enhanced, in a dose-dependent fashion, (1) the responsiveness of MEPM cells to prostaglandin E1-induced elevation of intracellular levels of cAMP, and (2) the responsiveness of cells to calcium ionophore (A23187) and melittin-induced synthesis of prostaglandins E2 and F2 alpha. Hormonal responsiveness of MEPM cells to EGF, prostaglandins and cAMP has been implicated as being involved in controlling various aspects of normal oro-facial development. We show here that EGF can potentiate hormonal responsiveness of these cells and thus allows consideration of EGF as a factor which may modulate hormonally regulated craniofacial growth and differentiation.


Subject(s)
Cyclic AMP/biosynthesis , Epidermal Growth Factor/pharmacology , Palate/embryology , Prostaglandins/biosynthesis , Animals , Calcimycin/pharmacology , Cells, Cultured , Embryo, Mammalian , Female , Kinetics , Melitten/pharmacology , Mice , Mice, Inbred C57BL , Palate/cytology , Palate/drug effects , Pregnancy
13.
J Craniofac Genet Dev Biol ; 5(4): 373-84, 1985.
Article in English | MEDLINE | ID: mdl-3001128

ABSTRACT

During embryonic development, facial and palate mesenchymal cells exhibit differential growth rates. Normal palatal growth is regulated in part by hormones and growth factors. Because hormonal responsiveness of some cells correlates with their cell density, we have investigated the relationship between embryonic palate mesenchymal cell population density and their ability to synthesize prostaglandins (PGs) and cyclic AMP. Primary cultures of palate mesenchymal cells exhibited typical lag, log, and stationary phases of growth with a doubling time of 32-34 hrs. The ability of cells to produce PGE2 in response to a calcium ionophore (A23187), an activator of phospholipase A2 (melittin), arachidonic acid, or serum was maximal during the period of early exponential growth. Prostaglandin F2 alpha synthesis in response to A23187 or arachidonic acid showed a similar transient increase also corresponding temporally to the period of early exponential growth. The ability to synthesize PGF2 alpha in response to melittin, however, failed to diminish after early exponential growth. The pattern of cAMP synthesis in response to isoproterenol and PGE1 was different from that seen for induced prostaglandin synthesis. A transient increase in sensitivity to isoproterenol and PGE1 was seen that corresponded temporally to the period of late exponential growth just prior to attainment of confluency. Decreased sensitivity to stimulation of either prostaglandin or cAMP production as the cells became confluent was shown to be a density-dependent phenomenon; confluent cultures that were subcultured to reestablish logarithmic growth exhibited density-dependent hormonal responses identical to those seen in primary cultures. The ability of palate mesenchymal cells to synthesize both prostaglandins and cAMP, thought to be critical for proper palatal development, might thus be related to local differential craniofacial growth rates.


Subject(s)
Cyclic AMP/biosynthesis , Mesoderm/metabolism , Palate/embryology , Prostaglandins/biosynthesis , Alprostadil/pharmacology , Animals , Arachidonic Acid , Arachidonic Acids/pharmacology , Blood , Calcimycin/pharmacology , Cell Count , Cell Division , Cells, Cultured , Dinoprost , Dinoprostone , Isoproterenol/pharmacology , Kinetics , Melitten/pharmacology , Mice , Mice, Inbred C57BL , Palate/drug effects , Palate/metabolism , Prostaglandins E/biosynthesis , Prostaglandins F/biosynthesis
14.
J Exp Zool ; 225(1): 43-52, 1983 Jan.
Article in English | MEDLINE | ID: mdl-6300280

ABSTRACT

The avian secondary palate exhibits the unique feature of a midline cleft. Cryostat sections indicated that although extensive contact between homologous shelves was present, chick palatal medial edge epithelium (MEE) failed to fuse. The failure of fusion and subsequent clefting of the avian palate were correlated with continued proliferation of the avian MEE, a failure of selective MEE cell death, and an absence of elevated levels of intracellular cAMP. Moreover, immunohistochemical staining for cAMP and microspectrophotometric quantitation of staining intensity indicated that staining of chick MEE was significantly (p less than .01) less than murine MEE at comparable gestational ages. These data indicate that differentiation of the avian secondary palate is fundamentally different than reported for the mammalian palate in that many developmental events known to be associated with normal mammalian palate formation (cessation of MEE proliferation, MEE cell death, elevated levels of MEE cAMP) fail to occur in the chick. The developing avian secondary palate, with its midline cleft, thus provides an interesting and useful model system with which to compare mammalian palate formation where the palate is normally fused in the midline.


Subject(s)
Palate/embryology , Animals , Cell Differentiation , Chick Embryo , Cyclic AMP/analysis , Epithelial Cells , Female , Mice , Mice, Inbred C57BL , Palate/analysis , Pregnancy
16.
Am J Drug Alcohol Abuse ; 9(4): 371-82, 1982.
Article in English | MEDLINE | ID: mdl-7188000

ABSTRACT

Recidivism rates and recidivism proportions for return to a state of daily opioid use following discharge from drug abuse treatment were studied for a sample of Black and White male daily opioid users. The rates and proportions were analyzed by treatment type and time in treatment. Significantly higher recidivism proportions were found for shorter tenure clients.


Subject(s)
Black or African American/psychology , Opioid-Related Disorders/therapy , White People/psychology , Follow-Up Studies , Humans , Male , Outcome and Process Assessment, Health Care , Recurrence , Time Factors
18.
Arch Gen Psychiatry ; 36(7): 772-80, 1979 Jul.
Article in English | MEDLINE | ID: mdl-454093

ABSTRACT

A sample of 3,131 persons from approximately 25,000 admitted to drug abuse treatment programs in the Drug Abuse Reporting Program during 1969-1972 were followed up in 1975-1976. Treatment groups included methadone hydrochloride maintenance, therapeutic community, outpatient drug free, outpatient detoxification, and a comparison group that completed intake but did not enter treatment. Outcome criterion measures (drug use, employment, criminality, and treatment readmissions) based on the first year after treatment were more favorable in the methadone maintenance, therapeutic community, and outpatient drug-free groups than in the outpatient detoxification and intake-only groups. Evaluation of differential outcomes and their relationships with pretreatment and during-treatment measures within each group indicated that pretreatment criminal history, during-treatment performance, and length of time in treatment were significantly related to posttreatment outcomes.


Subject(s)
Biotransformation , Inactivation, Metabolic , Methadone/therapeutic use , Substance-Related Disorders/therapy , Therapeutic Community , Adult , Age Factors , Analysis of Variance , Crime , Employment , Female , Follow-Up Studies , Humans , Male , Patient Readmission , United States
19.
Am J Drug Alcohol Abuse ; 6(4): 397-411, 1979.
Article in English | MEDLINE | ID: mdl-549469

ABSTRACT

A national sample of drug treatment clients admitted to the Drug Abuse Treatment Program (DARP) during 1969--1972 was followed approximately 5 years after admission. Subjective evaluations of treatment were compared for clients in methadone maintenance, therapeutic community, outpatient drug-free, and outpatient detoxification treatment programs, as well as a comparison group of clients who completed intake but received no treatment. These evaluations were also analyzed in relation to client background and treatment performance measures and post-treatment outcomes. The overall evaluation of DARP treatments by former clients was generally favorable and was highest for the DARP therapeutic community. Over two-thirds of the combined treatment sample indicated satisfaction with the treatment they received and a willingness to recommend it to others. Favorable evaluation was also positively related to during-treatment performance and tenure in DARP treatment as well as to behavioral outcomes after leaving treatment.


Subject(s)
Outcome and Process Assessment, Health Care , Substance-Related Disorders/rehabilitation , Adolescent , Adult , Ethnicity , Evaluation Studies as Topic , Hospitalization , Humans , Male , Methadone/therapeutic use , Opioid-Related Disorders/rehabilitation , Outpatient Clinics, Hospital , Social Adjustment , Social Environment , Therapeutic Community
20.
Am J Drug Alcohol Abuse ; 5(1): 1-22, 1978.
Article in English | MEDLINE | ID: mdl-696703

ABSTRACT

The present study was based on follow-up data on 1409 persons interviewed 4 to 6 years after admission to drug treatment in the Drug Abuse Reporting Program (DARP). The admissions to DARP occurred in 1969-1971, and for most persons the follow-up data included 3 or more years after termination of DARP treatment. The study focused on variations in alcohol consumption associated with post-DARP drug use and treatment status. The results indicated that use of alcohol and non-opioid drugs (particularly marijuana) tended to be correlated, but that this was not true of opioid drugs. For a small segment of the sample, evidence suggested that substitution of use may have occurred between alcohol and opioid drugs. Also, persons with post-DARP drug treatment tended to use less alcohol than persons without treatment. Interpretations and implications of these findings are discussed.


Subject(s)
Alcohol Drinking , Illicit Drugs , Mental Health Services , Pharmaceutical Preparations , Substance-Related Disorders , Adult , Female , Follow-Up Studies , Humans , Interview, Psychological , Male , Middle Aged , Regression Analysis , Substance-Related Disorders/therapy , Time Factors , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...